The company confirmed it will host a webcast and conference call at 4:30 p.m. ET on the designated date to discuss the status of the program. This follows data released in late June, where Cumberland reported that additional analyses of cardiac biomarkers reinforced the cardioprotective potential observed during Phase 2 trials of the drug. The market remains focused on whether the upcoming session will provide concrete steps toward the next stage of development for the candidate.
In section Market Quotes
Cumberland Pharmaceuticals Rallies Ahead of Ifetroban Update
Shares of Cumberland Pharmaceuticals surged 18% to $7.92 on Tuesday, extending a sharp 99% year-to-date rally. Investors are positioning themselves for an October 26 announcement concerning ifetroban, a drug candidate currently under investigation for treating cardiomyopathy linked to Duchenne muscular dystrophy.
Comments (0)
No comments yet. Be the first!